Adaptimmune Ther Ads (ADAP) 7.12 $ADAP Adaptimm
Post# of 273254
Posted On: 09/24/2016 3:05:22 AM
Adaptimmune Ther Ads (ADAP) 7.12 $ADAP
Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR(R) T-cell Therapies Towards Commercialization
GlobeNewswire - Mon Sep 19, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing agreement with PCT, a Caladrius company, ("PCT"
a subsidiary of Caladrius Biosciences (Nasdaq:CLBS) for the supply of Adaptimmune's SPEAR(R) T-cell therapies. Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant manufacturing unit at PCT as well as dedicated, specialist staff.
ADAP: 7.12 (unch), CLBS: 4.88 (+0.25)
Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune
GlobeNewswire - Mon Sep 19, 6:30AM CDT
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company", a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company or "PCT" with a select therapeutic development pipeline, today announces a new five-year strategic manufacturing services agreement under which PCT will produce SPEAR(R) T-cell therapies for Adaptimmune Therapeutics plc (NASDAQ:ADAP) ("Adaptimmune". PCT, through dedicated, specialized staff and facilities, will produce the SPEAR(R) T-cell products at its Allendale, New Jersey facility in a manner compliant with both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations.
ADAP: 7.12 (unch), CLBS: 4.88 (+0.25)
Adaptimmune to Participate in Two Upcoming Investor Conferences
GlobeNewswire - Thu Sep 08, 2:30PM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences:
ADAP: 7.12 (unch), MS: 31.91 (-0.33)
Adaptimmune Reports Second Quarter 2016 Financial Results
Globe Newswire - Mon Aug 08, 6:00AM CDT
- Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
ADAP: 7.12 (unch)
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR(R) T-cell Therapy in Myxoid Round Cell Liposarcoma
GlobeNewswire - Wed Aug 03, 3:23PM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR(R) T-cell therapy in myxoid round cell liposarcoma (MRCLS). This trial is not yet active at any investigational sites, and has not recruited any patients. This notification of partial clinical hold does not apply to any other Adaptimmune study.
ADAP: 7.12 (unch)
Adaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Tue Aug 02, 7:15AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended June 30, 2016 before the open of the U.S. markets on Monday August 8, 2016. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. Eastern Time (1:00 p.m. BST) on the same day at which time management will provide a business update and discuss the financial results for the second quarter of 2016.
ADAP: 7.12 (unch)
ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer
Maher Syed - Zacks Investment Research - Mon Aug 01, 5:13PM CDT
Here's why Adaptimmune therapeutics looks like an intriguing investment prospect right now.
ADAP: 7.12 (unch), GSK: 43.42 (-0.16)
Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR(R) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Globe Newswire - Thu Jul 28, 10:33AM CDT
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs
ADAP: 7.12 (unch)
Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System
GlobeNewswire - Tue Jun 21, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The new 10-year agreement augments Adaptimmune's exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS(TM))* for use in the manufacture of Adaptimmune's SPEAR(TM) T-cell therapies.
ADAP: 7.12 (unch)
Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR(TM) T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
GlobeNewswire - Sun Jun 05, 8:05AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an affinity enhanced SPEAR(TM) T-cell receptor therapy targeting the NY-ESO-1 cancer antigen, in patients with advanced tumors at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting.
ADAP: 7.12 (unch)
Adaptimmune to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 10:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 PM EDT (9:30 PM BST). The conference is being held at the Grand Hyatt in New York.
ADAP: 7.12 (unch)
Adaptimmune Announces Succession Plan for Chairman at End of 2016
GlobeNewswire - Tue May 24, 6:32AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company", a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of 2016.
ADAP: 7.12 (unch)
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company", a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.
MDGN: 5.54 (+0.16), ICPT: 166.23 (-4.24), ADAP: 7.12 (unch)
Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Thu May 19, 8:00AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 10:30 AM EDT (3:30 PM BST). The conference is being held at the Grand Hyatt in New York.
ADAP: 7.12 (unch)
Pfizer (PFE) Reveals Positive Phase III Data on Trumenba
Zacks Equity Research - Zacks Investment Research - Mon May 16, 9:03AM CDT
Pfizer (PFE) announced positive data from two phase III studies on Trumenba for providing protection against serogroup B meningococcal disease.
ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), ADAP: 7.12 (unch), BMY: 56.48 (+0.06)
New Strong Buy Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 12:03PM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday.
CABO: 578.73 (+1.70), ADAP: 7.12 (unch), DF: 16.50 (-0.11), BBL: 28.49 (-0.11), PAC: 90.70 (-0.38)
Bayer Stops Phase II Adempas Study Due to Safety Issues
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:33AM CDT
Bayer (BAYRY) has terminated a phase II study on Adempas in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias, with immediate effect.
ANIP: 66.64 (-0.17), ADAP: 7.12 (unch), BMY: 56.48 (+0.06)
Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR(R) T-cell Therapies Towards Commercialization
GlobeNewswire - Mon Sep 19, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing agreement with PCT, a Caladrius company, ("PCT"
a subsidiary of Caladrius Biosciences (Nasdaq:CLBS) for the supply of Adaptimmune's SPEAR(R) T-cell therapies. Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant manufacturing unit at PCT as well as dedicated, specialist staff. ADAP: 7.12 (unch), CLBS: 4.88 (+0.25)
Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune
GlobeNewswire - Mon Sep 19, 6:30AM CDT
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"
, a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company or "PCT" with a select therapeutic development pipeline, today announces a new five-year strategic manufacturing services agreement under which PCT will produce SPEAR(R) T-cell therapies for Adaptimmune Therapeutics plc (NASDAQ:ADAP) ("Adaptimmune". PCT, through dedicated, specialized staff and facilities, will produce the SPEAR(R) T-cell products at its Allendale, New Jersey facility in a manner compliant with both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations. ADAP: 7.12 (unch), CLBS: 4.88 (+0.25)
Adaptimmune to Participate in Two Upcoming Investor Conferences
GlobeNewswire - Thu Sep 08, 2:30PM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences:
ADAP: 7.12 (unch), MS: 31.91 (-0.33)
Adaptimmune Reports Second Quarter 2016 Financial Results
Globe Newswire - Mon Aug 08, 6:00AM CDT
- Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
ADAP: 7.12 (unch)
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR(R) T-cell Therapy in Myxoid Round Cell Liposarcoma
GlobeNewswire - Wed Aug 03, 3:23PM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR(R) T-cell therapy in myxoid round cell liposarcoma (MRCLS). This trial is not yet active at any investigational sites, and has not recruited any patients. This notification of partial clinical hold does not apply to any other Adaptimmune study.
ADAP: 7.12 (unch)
Adaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Tue Aug 02, 7:15AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended June 30, 2016 before the open of the U.S. markets on Monday August 8, 2016. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. Eastern Time (1:00 p.m. BST) on the same day at which time management will provide a business update and discuss the financial results for the second quarter of 2016.
ADAP: 7.12 (unch)
ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer
Maher Syed - Zacks Investment Research - Mon Aug 01, 5:13PM CDT
Here's why Adaptimmune therapeutics looks like an intriguing investment prospect right now.
ADAP: 7.12 (unch), GSK: 43.42 (-0.16)
Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR(R) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Globe Newswire - Thu Jul 28, 10:33AM CDT
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs
ADAP: 7.12 (unch)
Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System
GlobeNewswire - Tue Jun 21, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The new 10-year agreement augments Adaptimmune's exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS(TM))* for use in the manufacture of Adaptimmune's SPEAR(TM) T-cell therapies.
ADAP: 7.12 (unch)
Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR(TM) T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
GlobeNewswire - Sun Jun 05, 8:05AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an affinity enhanced SPEAR(TM) T-cell receptor therapy targeting the NY-ESO-1 cancer antigen, in patients with advanced tumors at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting.
ADAP: 7.12 (unch)
Adaptimmune to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 10:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 PM EDT (9:30 PM BST). The conference is being held at the Grand Hyatt in New York.
ADAP: 7.12 (unch)
Adaptimmune Announces Succession Plan for Chairman at End of 2016
GlobeNewswire - Tue May 24, 6:32AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"
, a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of 2016. ADAP: 7.12 (unch)
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"
, a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee. MDGN: 5.54 (+0.16), ICPT: 166.23 (-4.24), ADAP: 7.12 (unch)
Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Thu May 19, 8:00AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 10:30 AM EDT (3:30 PM BST). The conference is being held at the Grand Hyatt in New York.
ADAP: 7.12 (unch)
Pfizer (PFE) Reveals Positive Phase III Data on Trumenba
Zacks Equity Research - Zacks Investment Research - Mon May 16, 9:03AM CDT
Pfizer (PFE) announced positive data from two phase III studies on Trumenba for providing protection against serogroup B meningococcal disease.
ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), ADAP: 7.12 (unch), BMY: 56.48 (+0.06)
New Strong Buy Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 12:03PM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday.
CABO: 578.73 (+1.70), ADAP: 7.12 (unch), DF: 16.50 (-0.11), BBL: 28.49 (-0.11), PAC: 90.70 (-0.38)
Bayer Stops Phase II Adempas Study Due to Safety Issues
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:33AM CDT
Bayer (BAYRY) has terminated a phase II study on Adempas in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias, with immediate effect.
ANIP: 66.64 (-0.17), ADAP: 7.12 (unch), BMY: 56.48 (+0.06)
(0)
(0)Scroll down for more posts ▼